WAVE LIFE SCIENCES LTD. (WVE) Current Ratio
- Current ratio · latest quarter: Value 9.99×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 9.99× | Current assets / current liabilities. $507.51M ÷ $50.81M ≈ 9.99× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 507.51M USD | Assets, Current |
| Current obligations | 50.81M USD | Liabilities, Current |
| Cash and equivalents | 368.01M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 888.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 20.36M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $507.51M | $50.81M | $368.01M | (m) | $888.00K | (m) | $20.36M | (m) | 9.99× |
| 2026-03-31 | $561.27M | $49.83M | $544.59M | (m) | $0.00 | (m) | $19.06M | (m) | 11.26× |
| 2025-12-31 | $614.81M | $95.06M | $602.07M | (m) | $1.28M | (m) | $15.70M | (m) | 6.47× |
| 2025-09-30 | $215.49M | $85.90M | $196.22M | (m) | $10.00M | (m) | $14.49M | (m) | 2.51× |
| 2025-06-30 | $223.56M | $87.41M | $208.48M | (m) | $1.62M | (m) | $14.66M | (m) | 2.56× |
| 2025-03-31 | $257.98M | $87.37M | $243.07M | (m) | (m) | (m) | $14.36M | (m) | 2.95× |
| 2024-12-31 | $320.39M | $110.95M | $302.08M | (m) | $1.42M | (m) | $16.26M | (m) | 2.89× |
| 2024-09-30 | $324.51M | $170.73M | $310.95M | (m) | $0.00 | (m) | $12.78M | (m) | 1.90× |
| 2024-06-30 | $172.07M | $173.13M | $153.96M | (m) | $1.29M | (m) | $18.15M | (m) | 0.99× |
| 2024-03-31 | $196.77M | $165.87M | $180.92M | (m) | $0.00 | (m) | $11.73M | (m) | 1.19× |
| 2023-12-31 | $235.37M | $186.44M | $200.35M | (m) | $21.09M | (m) | $12.84M | (m) | 1.26× |
| 2023-09-30 | $158.57M | $99.98M | $139.94M | (m) | $7.00M | (m) | $12.61M | (m) | 1.59× |
| 2023-06-30 | $184.71M | $140.23M | $172.97M | (m) | (m) | (m) | $12.38M | (m) | 1.32× |
| 2023-03-31 | $219.59M | $132.57M | $207.56M | (m) | (m) | (m) | $11.91M | (m) | 1.66× |
| 2022-12-31 | $98.54M | $71.52M | $88.50M | (m) | (m) | (m) | $16.91M | (m) | 1.38× |
| 2022-09-30 | $131.43M | $64.26M | $96.95M | (m) | (m) | (m) | $15.93M | (m) | 2.05× |
| 2022-06-30 | $160.11M | $64.08M | $123.16M | (m) | (m) | (m) | $11.17M | (m) | 2.50× |
| 2022-03-31 | $124.38M | $58.49M | $61.71M | (m) | (m) | (m) | $9.85M | (m) | 2.13× |
| 2021-12-31 | $162.56M | $64.20M | $150.56M | (m) | (m) | (m) | $7.28M | (m) | 2.53× |
| 2021-09-30 | $157.99M | $31.64M | $123.90M | (m) | $22.50M | (m) | $7.44M | (m) | 4.99× |
| 2021-06-30 | $159.43M | $46.72M | $143.84M | (m) | $0.00 | (m) | $8.65M | (m) | 3.41× |
| 2021-03-31 | $194.54M | $48.68M | $148.53M | (m) | $30.00M | (m) | $13.42M | (m) | 4.00× |
| 2020-12-31 | $230.04M | $121.04M | $184.50M | (m) | $30.00M | (m) | $13.79M | (m) | 1.90× |
| 2020-09-30 | $258.43M | $109.66M | $216.36M | (m) | $30.00M | (m) | $9.70M | (m) | 2.36× |
| 2020-06-30 | $146.83M | $110.45M | $94.05M | (m) | $30.00M | (m) | $13.91M | (m) | 1.33× |
| 2020-03-31 | $149.79M | $118.88M | $120.95M | (m) | (m) | (m) | $16.49M | (m) | 1.26× |
| 2019-12-31 | $185.48M | $118.15M | $147.16M | (m) | $20.00M | (m) | $9.07M | (m) | 1.57× |
| 2019-09-30 | $250.26M | $133.41M | $209.01M | (m) | $20.00M | (m) | $20.22M | (m) | 1.88× |
| 2019-06-30 | $289.59M | $124.08M | $252.91M | (m) | $20.00M | (m) | $11.46M | (m) | 2.33× |
| 2019-03-31 | $315.03M | $131.88M | $287.57M | (m) | $10.00M | (m) | $14.58M | (m) | 2.39× |
| 2018-12-31 | $202.27M | $130.04M | $174.82M | (m) | $10.00M | (m) | $13.09M | (m) | 1.56× |
| 2018-09-30 | $233.16M | $125.80M | $210.49M | (m) | $10.00M | (m) | $11.96M | (m) | 1.85× |
| 2018-06-30 | $267.67M | $43.78M | $241.43M | (m) | $15.00M | (m) | $7.15M | (m) | 6.11× |
| 2018-03-31 | $117.96M | $16.30M | $110.49M | (m) | (m) | (m) | $8.01M | (m) | 7.24× |
| 2017-12-31 | $150.49M | $18.19M | $142.50M | (m) | $1.00M | (m) | $7.60M | (m) | 8.27× |
| 2017-09-30 | $173.83M | $15.12M | $168.46M | (m) | (m) | (m) | $4.71M | (m) | 11.50× |
| 2017-06-30 | $201.22M | $15.55M | $197.39M | (m) | (m) | (m) | $7.98M | (m) | 12.94× |
| 2017-03-31 | $132.78M | $14.07M | $129.48M | (m) | (m) | (m) | $7.40M | (m) | 9.44× |
| 2016-12-31 | $151.99M | $12.15M | $150.29M | (m) | (m) | (m) | $4.94M | (m) | 12.50× |
| 2016-09-30 | $172.14M | $11.43M | $169.01M | (m) | $2.50M | (m) | $3.83M | (m) | 15.07× |
| 2016-06-30 | $183.94M | $8.65M | $181.76M | (m) | (m) | (m) | $3.90M | (m) | 21.27× |
| 2016-03-31 | $154.00M | $3.77M | $153.40M | (m) | (m) | (m) | $2.44M | (m) | 40.85× |
| 2015-12-31 | $161.38M | $3.82M | $161.22M | (m) | (m) | (m) | $2.81M | (m) | 42.27× |
| 2015-09-30 | $67.99M | $3.47M | $66.04M | (m) | (m) | (m) | $2.88M | (m) | 19.57× |
| 2014-12-31 | $1.49M | $882.00K | $1.05M | (m) | $200.00K | (m) | $125.00K | (m) | 1.69× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |